Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 3Myeloproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Hereditary Sensory and Autonomic Neuropathies 2Recurrence 1Primary Myelofibrosis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 36fludarabine phosphate 32Tacrolimus 28Busulfan 24Peripheral Blood Stem Cell Transplantation 23Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 18Methotrexate 16fludarabine 14ruxolitinib 13Melphalan 12Cyclosporine 12thymoglobulin 8Stem Cell Transplantation 8Radiotherapy 8Methylprednisolone 8Sirolimus 6Prednisone 6Cord Blood Stem Cell Transplantation 6Specimen Handling 5Filgrastim 5Etoposide 5Alemtuzumab 5merphos 4itacitinib 4Imatinib Mesylate 4INCB039110 4Hematopoietic Stem Cell Transplantation 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Primary Myelofibrosis × parsaclisib × Clear all
NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡